{
    "id": 13625,
    "fullName": "CEBPA mutant",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "CEBPA mutant indicates an unspecified mutation in the CEBPA gene.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "category",
    "gene": {
        "id": 1050,
        "geneSymbol": "CEBPA",
        "terms": [
            "CEBPA",
            "C/EBP-alpha",
            "CEBP"
        ]
    },
    "variant": "mutant",
    "createDate": "11/04/2015",
    "updateDate": "03/16/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 13266,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, patient-derived acute myeloid leukemia (AML) cells harboring biallelic CEBPA mutations demonstrated increased sensitivity to AZD1480 compared to control AML cells in culture (PMID: 27034432).",
            "molecularProfile": {
                "id": 13812,
                "profileName": "CEBPA mutant"
            },
            "therapy": {
                "id": 652,
                "therapyName": "AZD1480",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11014,
                    "pubMedId": 27034432,
                    "title": "Chemo-genomic interrogation of CEBPA mutated AML reveals recurrent CSF3R mutations and subgroup sensitivity to JAK inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27034432"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6167,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Prognostic",
            "efficacyEvidence": "In clinical analyses, biallelic CEBPA mutations were associated with favorable clinical outcome in patients with cytogenetically normal acute myeloid leukemia (PMID: 26601784, PMID: 19171880, PMID: 20038735, PMID: 22915647).",
            "molecularProfile": {
                "id": 13812,
                "profileName": "CEBPA mutant"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5328,
                    "pubMedId": 26601784,
                    "title": "The multifaceted functions of C/EBP\u03b1 in normal and malignant haematopoiesis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26601784"
                },
                {
                    "id": 5336,
                    "pubMedId": 19171880,
                    "title": "Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19171880"
                },
                {
                    "id": 5337,
                    "pubMedId": 20038735,
                    "title": "Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20038735"
                },
                {
                    "id": 5338,
                    "pubMedId": 22915647,
                    "title": "A novel hierarchical prognostic model of AML solely based on molecular mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22915647"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 18064,
            "approvalStatus": "Guideline",
            "evidenceType": "Prognostic",
            "efficacyEvidence": "CEBPA biallelic mutations are associated with a favorable prognosis in patients with non-APL acute myeloid leukemia (NCCN.org).",
            "molecularProfile": {
                "id": 13812,
                "profileName": "CEBPA mutant"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13264,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, patient-derived acute myeloid leukemia (AML) cells harboring biallelic CEBPA mutations demonstrated increased sensitivity to Momelotinib (CYT387) compared to control AML cells in culture (PMID: 27034432).",
            "molecularProfile": {
                "id": 13812,
                "profileName": "CEBPA mutant"
            },
            "therapy": {
                "id": 823,
                "therapyName": "Momelotinib",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11014,
                    "pubMedId": 27034432,
                    "title": "Chemo-genomic interrogation of CEBPA mutated AML reveals recurrent CSF3R mutations and subgroup sensitivity to JAK inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27034432"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13263,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, patient-derived acute myeloid leukemia (AML) cells harboring biallelic CEBPA mutations demonstrated increased sensitivity to Jakafi (ruxolitinib) compared to control AML cells in culture (PMID: 27034432).",
            "molecularProfile": {
                "id": 13812,
                "profileName": "CEBPA mutant"
            },
            "therapy": {
                "id": 907,
                "therapyName": "Ruxolitinib",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11014,
                    "pubMedId": 27034432,
                    "title": "Chemo-genomic interrogation of CEBPA mutated AML reveals recurrent CSF3R mutations and subgroup sensitivity to JAK inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27034432"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13265,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, patient-derived acute myeloid leukemia (AML) cells harboring biallelic CEBPA mutations demonstrated increased sensitivity to Xeljanz (tofacitinib) compared to control AML cells in culture (PMID: 27034432).",
            "molecularProfile": {
                "id": 13812,
                "profileName": "CEBPA mutant"
            },
            "therapy": {
                "id": 941,
                "therapyName": "Tofacitinib",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11014,
                    "pubMedId": 27034432,
                    "title": "Chemo-genomic interrogation of CEBPA mutated AML reveals recurrent CSF3R mutations and subgroup sensitivity to JAK inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27034432"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3612,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Prognostic",
            "efficacyEvidence": "In clinical analyses, mutations in GATA2 were associated with better overall survival in patients with cytogenetically normal acute myeloid leukemia (CN-AML) harboring biallelic CEBPA gene mutations (PMID: 22814295, PMID: 23521373, PMID: 25241285).",
            "molecularProfile": {
                "id": 22783,
                "profileName": "CEBPA mut GATA2 mut"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 3883,
                    "pubMedId": 22814295,
                    "title": "GATA2 mutations are frequent in intermediate-risk karyotype AML with biallelic CEBPA mutations and are associated with favorable prognosis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22814295"
                },
                {
                    "id": 5352,
                    "pubMedId": 23521373,
                    "title": "CEBPA double-mutated acute myeloid leukaemia harbours concomitant molecular mutations in 76\u00b78% of cases with TET2 and GATA2 alterations impacting prognosis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23521373"
                },
                {
                    "id": 5353,
                    "pubMedId": 25241285,
                    "title": "GATA2 mutations in patients with acute myeloid leukemia-paired samples analyses show that the mutation is unstable during disease evolution.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25241285"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        }
    ],
    "molecularProfiles": [
        {
            "id": 13812,
            "profileName": "CEBPA mutant",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 13813,
            "profileName": "CEBPA mut GATA2 T354M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 22783,
            "profileName": "CEBPA mut GATA2 mut",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}